3-(4-BOC-piperazino)-2-chloropyridine

Catalog No. :
ACBYZN502
CAS No. :
633283-64-4
Molecular Formula :
C14H20ClN3O2
Molecular Weight :
297.79

IUPAC Name:tert-butyl 4-(2-chloropyridin-3-yl)piperazine-1-carboxylate

3-(4-BOC-piperazino)-2-chloropyridine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg97%$194.00Login to see priceInquiryInquiry
1g97%$446.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-(4-BOC-piperazino)-2-chloropyridine
IUPAC Nametert-butyl 4-(2-chloropyridin-3-yl)piperazine-1-carboxylate
Molecular FormulaC14H20ClN3O2
Molecular Weight297.79
SMILESClC1=NC=CC=C1N2CCN(C(OC(C)(C)C)=O)CC2
InChI KeyWZDUKAPYVNYSAV-UHFFFAOYSA-N
Synonym3-(4-BOC-piperazino)-2-chloropyridine;4-(2-CHLORO-3-PYRIDINYL)-1-PIPERAZINECARBOXYLIC ACID 1,1-DIMETHYLETHYL ESTER;1-Piperazinecarboxylic acid, 4-(2-chloro-3-pyridinyl)-, 1,1-dimethylethyl ester
CAS No.633283-64-4

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACBYZN502 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  2. Plus
  3. ACGZTI950 route compound structure diagram
    ACGZTI95078607-36-0 In Stock
  4. Then
  5. ACBYZN502 route product structure diagram
    ACBYZN502633283-64-4
Inquiry

2. ACBYZN502 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  2. Plus
  3. ACHTRE764 route compound structure diagram
    ACHTRE76452200-48-3 In Stock
  4. Then
  5. ACBYZN502 route product structure diagram
    ACBYZN502633283-64-4
Inquiry

Comments (0)